Geetha Shankar
About Geetha Shankar
Geetha Shankar - Head Of Clinical Development Oncology
Geetha Shankar is the Head Of Clinical Development Oncology and Head of the Amunix site. With over 25 years of experience in drug discovery and development, she has a comprehensive background from high throughput screening to clinical development phases and regulatory filings. Her current role sees her leading initiatives at Amunix, bringing innovative oncology solutions to market.
Geetha Shankar's Educational Background and Expertise
Geetha Shankar earned her Ph.D. in Molecular Pharmacology from Northwestern University School of Medicine. She also holds an M.S. in Medicinal Chemistry from the University of the Sciences in Philadelphia, and a B.Pharm. from the College of Pharmacy in Bangalore, India. Her expertise spans from high throughput screening and drug discovery to advanced clinical development (IND to phase III), regulatory filings, and market access.
Geetha Shankar's Tenure at Genentech
Geetha Shankar spent 10 years at Genentech as Group Clinical Science Director. During her tenure, she oversaw US, EU, and global approvals of Tecentriq for non-small cell lung cancer. Shankar played a key role in the PI3K program and worked on proof-of-concept studies in breast and lung cancer indications.
Geetha Shankar's Role at Exelixis
At Exelixis, Geetha Shankar worked for six years, initially as a team leader on drug discovery projects before transitioning to clinical development. She contributed significantly to early trials for cabozantinib in medullary thyroid cancer, furthering the development of this important oncology drug.
Career at Ceretek LLC
Geetha Shankar also worked at Ceretek LLC, an oncology startup focused on lipid G-protein coupled receptors. Her work at Ceretek allowed her to further specialize in innovative oncology solutions, leveraging her extensive background in molecular pharmacology and clinical development.